 |
|
 |
 |

Home > Company Index > Drugs > Drug Manufacturers - Major > Sanofi-Synthélabo
 |
Sanofi-Synthélabo |
 |
 |
 |
NEWS FROM THE WIRES |
 |
Chile's Jan-June bank earnings up 101 pct yr/yr Jul 23 2001 09:54 AM PDT
U.S. stocks pinned near lows, profit jitters return Jul 23 2001 09:54 AM PDT
> More WIRE STORIES about this company
PROFILE |
 |
"À votre santé!" French drugmaker Sanofi-Synthélabo isn't just concerned with the health of Europe; it wants to make sure "les Américains" are in the pink, too. The merger of Sanofi and Synthélabo was designed to catapult the new company to a prime position in the US market. The company specializes in cardiovascular, central nervous system, oncology, and internal medicine formulations; approximately 50 new drugs (more than half in clinical trials) are in its pipeline. It also makes OTC and generic drugs. Its predecessors sold their cosmetic and perfume operations before merging, along with some drugs that raised monopoly concerns. TotalFina Elf is cutting its stake, which stands at about 30%; L'Oréal owns 19%.
COMPETITION |
 |
Aventis (AVE)
Eli Lilly and Company (LLY)
Merck & Co., Inc. (MRK)
|
 |
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
1999 Sales (mil.): 5,387.50
1-Yr. Sales Growth: 17.2%
Employees: 29,312
Revenue per employee: $183,798.44
KEY PEOPLE |
 |
Jean-François Dehecq
CEO
Jean Claude Leroy
CFO
CONTACT INFO |
 |
174 avenue de France
75635 Paris Cedex 13, France
Phone: 33-1-53-77-44-45
Fax: 33-1-53-77-42-96
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |